Roche intends to launch SARS-CoV-2 antigen test in suspected COVID-patients

▴ Roche intends to launch SARS-CoV-2 antigen test in suspected COVID-patients
These fully automated systems can provide test results in 18 minutes for a single test, excluding time for sample collection, transport, and preparation

Roche announced that it intends to launch a high-volume SARS-CoV-2 Antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The test is planned to be made available at the end of 2020 for markets accepting the CE Mark. Roche also intends to file for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA).

The Elecsys SARS-CoV-2 Antigen test is a highly accurate laboratory immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of SARS-CoV-2. The test is performed by healthcare professionals and uses nasopharyngeal or oropharyngeal swab samples from patients with signs and symptoms suggestive of COVID-19 or people with either known or suspected exposure to SARS-CoV-2.

The Elecsys SARS-CoV-2 Antigen immunoassay runs on all cobas e immunochemistry analysers which are widely available around the world. These fully automated systems can provide test results in 18 minutes for a single test (excluding time for sample collection, transport, and preparation), with a throughput of up to 300 tests per hour from a single analyser, depending on the analyser. A laboratory-based automated antigen assay allows for cost and error reduction due to the removal of manual handling as well as fast turn-around times and high test throughput.

Thomas Schinecker, CEO Roche Diagnostics, stated, “We are aware that governments and healthcare systems are under intense pressure to increase SARS-CoV-2 testing capacity to effectively manage the spread of the virus. A high-volume antigen test is a valuable addition to the testing portfolio for helping diagnose SARS-CoV-2 infection. Being able to quickly and correctly identify if someone has a SARS-CoV-2 infection is critical to informing patient management decisions and containing the spread of COVID-19. Roche remains committed to supporting governments, healthcare professionals and patients to fight this pandemic with the help of our diagnostics solutions.”

The test will be another addition to the comprehensive Roche diagnostic portfolio of solutions to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care. These solutions include both tests to detect an acute SARS-CoV-2 infection and tests measuring the body’s immune response upon infection or vaccination.

Roche’s Elecsys SARS-CoV-2 Antigen test is an immunoassay intended for the qualitative detection of a specific antigen of SARS-CoV-2 present in the respiratory tract including nasopharynx and oropharynx. The Elecsys SARS-CoV-2 Antigen test is performed by healthcare professionals and could be used as an alternative or in conjunction with PCR testing. This is highly beneficial where reliable laboratory PCR testing is not available or where there are challenges in a testing capacity. A positive result with the Elecsys SARS-CoV-2 Antigen test most likely indicates an active SARS-CoV-2 infection. A negative result may require to be confirmed with a PCR test or repeated (antigen test) after one to two days if other clinical indications point to a SARS-CoV-2 infection. Performance evaluations around the sensitivity and specificity of the test are ongoing and will be shared at the time of launch.

An antigen test detects proteins which are structural or functional components of a pathogen and are thus very specific to that pathogen. In this case, the test would provide a qualitative “yes/no” answer on the presence of the pathogen in the patient sample. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a positive result.

In general, antigen tests have high specificity, though are not as sensitive as PCR tests that amplify the target viral DNA or RNA sequence in order to generate a quantifiable signal to indicate the presence of the virus in a sample. Therefore, to make up for the potential decrease in sensitivity of an antigen test, negative results should be analysed together with additional patient factors, such as COVID-19 exposure history, clinical symptoms, additional test results to help guide the diagnosis and subsequent treatment of the patient.

Tags : #Roche #LatestNewsonRoche15thOct #LatestPharmaNews15thOct #ThomasSchineckerofRoche #NewAntigenTestforCOVID-1915thOct #PCRTestforCOVIDPatients

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025
The University of Leeds and Sri Balaji Vidyapeeth Host 3rd International Health and Research Convention to Advance Global Healthcare and Medical ResearchFebruary 17, 2025
When ‘You Don’t Look Sick’ Becomes a Death Sentence for Chronic Illness PatientsFebruary 17, 2025
7 Essential Tips for Keeping Your Liver HealthyFebruary 17, 2025
Apollo Hospitals to Host International Health Dialogue 2025 in New Delhi: A Global Summit on Patient Safety & Digital InnovationFebruary 17, 2025
Distractions significantly delay remote drivers’ reaction timeFebruary 17, 2025
Narayana Health SRCC Children's Hospital, Mumbai Observes International Childhood Cancer Day with Muskan Ki Mehfil—A Tribute to Courage and HopeFebruary 17, 2025
Eating from Plastic Containers? You Might Be Ingesting a Heart AttackFebruary 17, 2025
Lost Memories? Scientists Uncover the Mysterious Neurons That Could Save Your BrainFebruary 17, 2025
Lost Memories? Scientists Uncover the Mysterious Neurons That Could Save Your BrainFebruary 17, 2025
When the Mind Hurts, the Body Follows: How Depression Creates Havoc on Physical HealthFebruary 14, 2025